OmniAb, Inc. (NASDAQ:OABI – Get Free Report) reached a new 52-week low on Wednesday . The stock traded as low as $4.08 and last traded at $4.26, with a volume of 357382 shares. The stock had previously closed at $4.14. Analyst Ratings Changes Several equities analysts have commented on OABI shares. Benchmark reaffirmed a “buy” […]
OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
OmniAb, Inc. (NASDAQ:OABI – Get Free Report) CEO Matthew W. Foehr bought 240,000 shares of OmniAb stock in a transaction on Friday, May 24th. The shares were purchased at an average cost of $4.42 per share, for a total transaction of $1,060,800.00. Following the acquisition, the chief executive officer now owns 3,536,665 shares in the […]
BRIDGEWATER, NJ / ACCESSWIRE / May 29, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in